SK9452002A3 - Indole derivatives, pharmaceutical composition containing the same and their use - Google Patents
Indole derivatives, pharmaceutical composition containing the same and their use Download PDFInfo
- Publication number
- SK9452002A3 SK9452002A3 SK945-2002A SK9452002A SK9452002A3 SK 9452002 A3 SK9452002 A3 SK 9452002A3 SK 9452002 A SK9452002 A SK 9452002A SK 9452002 A3 SK9452002 A3 SK 9452002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- indole
- piperazin
- propyl
- phenylsulfanyl
- phenoxy
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title claims description 23
- 229940054051 antipsychotic indole derivative Drugs 0.000 title claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 239000003446 ligand Substances 0.000 claims abstract description 16
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims abstract description 7
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
- -1 C 2 .6alkenyl Chemical group 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 21
- 108020003175 receptors Proteins 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 229960003638 dopamine Drugs 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 208000025966 Neurological disease Diseases 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 230000000697 serotonin reuptake Effects 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- DYMNLOXRYLTXGI-UHFFFAOYSA-N 3-chloro-4-[4-[4-(1h-indol-4-yl)piperazin-1-yl]butoxy]benzonitrile Chemical compound ClC1=CC(C#N)=CC=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 DYMNLOXRYLTXGI-UHFFFAOYSA-N 0.000 claims description 3
- TYQBVXJXJWZKAC-UHFFFAOYSA-N 4-[4-[3-(4-bromo-2,6-difluorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound FC1=CC(Br)=CC(F)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 TYQBVXJXJWZKAC-UHFFFAOYSA-N 0.000 claims description 3
- WMBXEFHEVDSWQN-UHFFFAOYSA-N 4-[4-[4-(2-propan-2-ylphenyl)sulfanylbutyl]piperazin-1-yl]-1h-indole Chemical compound CC(C)C1=CC=CC=C1SCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 WMBXEFHEVDSWQN-UHFFFAOYSA-N 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
- DOCQXUPCBKYRDK-UHFFFAOYSA-N 4-[4-[3-(2,4-difluorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound FC1=CC(F)=CC=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 DOCQXUPCBKYRDK-UHFFFAOYSA-N 0.000 claims description 2
- YJSOYQIULDLRHZ-UHFFFAOYSA-N 4-[4-[4-(2,6-dichloro-4-fluorophenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC(F)=CC(Cl)=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 YJSOYQIULDLRHZ-UHFFFAOYSA-N 0.000 claims description 2
- IESXLZWJNQTGKR-UHFFFAOYSA-N 4-[4-[4-(2-bromo-4-fluorophenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC(F)=CC=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 IESXLZWJNQTGKR-UHFFFAOYSA-N 0.000 claims description 2
- ZOXRKKZOHXAVAF-UHFFFAOYSA-N 4-[4-[4-(2-chlorophenyl)sulfanylbutyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC=C1SCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 ZOXRKKZOHXAVAF-UHFFFAOYSA-N 0.000 claims description 2
- PAOXANAZBXVLKE-UHFFFAOYSA-N 4-[4-[4-(2-ethylphenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound CCC1=CC=CC=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 PAOXANAZBXVLKE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- XMGGBDOOGVBWMX-UHFFFAOYSA-N ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F Chemical compound ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F XMGGBDOOGVBWMX-UHFFFAOYSA-N 0.000 claims description 2
- GHPGQKRCBQPLRC-UHFFFAOYSA-N ClC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1 Chemical compound ClC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1 GHPGQKRCBQPLRC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 2
- MVAMMPCMASUYCZ-UHFFFAOYSA-N 4-[4-[3-(2,6-dichlorophenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC(Cl)=C1SCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 MVAMMPCMASUYCZ-UHFFFAOYSA-N 0.000 claims 1
- QKGJFOAIPFGKHD-UHFFFAOYSA-N 4-[4-[3-(2-chloro-4-fluorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC(F)=CC=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 QKGJFOAIPFGKHD-UHFFFAOYSA-N 0.000 claims 1
- UHBOJWLZGGPCJB-UHFFFAOYSA-N 4-[4-[3-(3-bromophenyl)sulfanylpropyl]piperazin-1-yl]-1H-indole 4-[4-[3-[4-(trifluoromethoxy)phenyl]sulfanylpropyl]piperazin-1-yl]-1H-indole Chemical compound BrC=1C=C(C=CC1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC(OC1=CC=C(C=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F UHBOJWLZGGPCJB-UHFFFAOYSA-N 0.000 claims 1
- INIDCHLQRPEVNJ-UHFFFAOYSA-N 4-[4-[4-(2-methoxyphenoxy)butyl]piperazin-1-yl]-1H-indole 4-[4-[3-(2-propan-2-ylphenyl)sulfanylpropyl]piperazin-1-yl]-1H-indole Chemical compound COC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.C(C)(C)C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 INIDCHLQRPEVNJ-UHFFFAOYSA-N 0.000 claims 1
- ZKEWPPMKIIOOGR-UHFFFAOYSA-N BrC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound BrC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 ZKEWPPMKIIOOGR-UHFFFAOYSA-N 0.000 claims 1
- ZWPAGAMKRSICCT-UHFFFAOYSA-N ClC1=C(C(=CC=C1)Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(C=CC(=C1)F)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC1=C(C(=CC=C1)Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(C=CC(=C1)F)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 ZWPAGAMKRSICCT-UHFFFAOYSA-N 0.000 claims 1
- 102000003962 Dopamine D4 receptors Human genes 0.000 claims 1
- 108090000357 Dopamine D4 receptors Proteins 0.000 claims 1
- RGCOZXFJTFMHGE-UHFFFAOYSA-N FC(C1=CC=C(C=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F.COC=1C=C(C=CC1OC)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound FC(C1=CC=C(C=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F.COC=1C=C(C=CC1OC)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 RGCOZXFJTFMHGE-UHFFFAOYSA-N 0.000 claims 1
- ISUQQSGQXIMSMI-UHFFFAOYSA-N FC1=CC=C(C=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound FC1=CC=C(C=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 ISUQQSGQXIMSMI-UHFFFAOYSA-N 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 58
- 238000000034 method Methods 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- YZKSXUIOKWQABW-UHFFFAOYSA-N 4-piperazin-1-yl-1h-indole Chemical compound C1CNCCN1C1=CC=CC2=C1C=CN2 YZKSXUIOKWQABW-UHFFFAOYSA-N 0.000 description 5
- 102000017911 HTR1A Human genes 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 230000002152 alkylating effect Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 229950002475 mesilate Drugs 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229950004288 tosilate Drugs 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 239000003727 serotonin 1A antagonist Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GRPVXZDDHARJSD-UHFFFAOYSA-N 1-(3-bromopropoxy)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1OCCCBr GRPVXZDDHARJSD-UHFFFAOYSA-N 0.000 description 2
- XIZQOLANYHNJAZ-UHFFFAOYSA-N 1-(3-bromopropylsulfanyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1SCCCBr XIZQOLANYHNJAZ-UHFFFAOYSA-N 0.000 description 2
- KUAPPJSILOMQPC-UHFFFAOYSA-N 2-chloro-4-fluorobenzenethiol Chemical compound FC1=CC=C(S)C(Cl)=C1 KUAPPJSILOMQPC-UHFFFAOYSA-N 0.000 description 2
- OVIBPPNRGNCGPI-UHFFFAOYSA-N 3,5-dibromo-4-[3-[4-(1h-indol-4-yl)piperazin-1-yl]propoxy]benzonitrile Chemical compound BrC1=CC(C#N)=CC(Br)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 OVIBPPNRGNCGPI-UHFFFAOYSA-N 0.000 description 2
- ITVCDURMQFFGRC-UHFFFAOYSA-N 3-[4-[4-(1h-indol-4-yl)piperazin-1-yl]butoxy]benzonitrile Chemical compound N#CC1=CC=CC(OCCCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 ITVCDURMQFFGRC-UHFFFAOYSA-N 0.000 description 2
- SEWUFOUJBBKRBU-UHFFFAOYSA-N 4-[4-[2-(2,3-dichlorophenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC(SCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1Cl SEWUFOUJBBKRBU-UHFFFAOYSA-N 0.000 description 2
- WEMHQWCEPWQOEE-UHFFFAOYSA-N 4-[4-[2-(2,6-dimethylphenoxy)ethyl]piperazin-1-yl]-1h-indole Chemical compound CC1=CC=CC(C)=C1OCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 WEMHQWCEPWQOEE-UHFFFAOYSA-N 0.000 description 2
- MJKPDUXCRONCGU-UHFFFAOYSA-N 4-[4-[2-(2-bromo-4,6-difluorophenoxy)ethyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC(F)=CC(F)=C1OCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 MJKPDUXCRONCGU-UHFFFAOYSA-N 0.000 description 2
- IHPGJGDGEWCKAT-UHFFFAOYSA-N 4-[4-[2-(2-chloro-4-fluorophenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC(F)=CC=C1SCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 IHPGJGDGEWCKAT-UHFFFAOYSA-N 0.000 description 2
- QJRQMLPRXFAYSH-UHFFFAOYSA-N 4-[4-[3-(2,6-dichloro-4-fluorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC(F)=CC(Cl)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 QJRQMLPRXFAYSH-UHFFFAOYSA-N 0.000 description 2
- UQEFMXMIVKTFAE-UHFFFAOYSA-N 4-[4-[3-(3,4-dimethylphenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound C1=C(C)C(C)=CC=C1SCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 UQEFMXMIVKTFAE-UHFFFAOYSA-N 0.000 description 2
- RFTHSYGISABOIO-UHFFFAOYSA-N 4-[4-[3-[4-(trifluoromethyl)phenyl]sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound C1=CC(C(F)(F)F)=CC=C1SCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 RFTHSYGISABOIO-UHFFFAOYSA-N 0.000 description 2
- UBGSZRKTQKIXSO-UHFFFAOYSA-N 4-[4-[4-(2-chloro-5-methylphenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound CC1=CC=C(Cl)C(OCCCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 UBGSZRKTQKIXSO-UHFFFAOYSA-N 0.000 description 2
- LUJVJCPIYINSKI-UHFFFAOYSA-N 4-[4-[4-(2-methoxyphenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound COC1=CC=CC=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 LUJVJCPIYINSKI-UHFFFAOYSA-N 0.000 description 2
- ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 101150015707 HTR1A gene Proteins 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- WQJFIWXYPKYBTO-UHFFFAOYSA-N indole-1-acetic acid Chemical class C1=CC=C2N(CC(=O)O)C=CC2=C1 WQJFIWXYPKYBTO-UHFFFAOYSA-N 0.000 description 2
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- KRVOJOCLBAAKSJ-RDTXWAMCSA-N (2R,3R)-nemonapride Chemical compound C1=C(Cl)C(NC)=CC(OC)=C1C(=O)N[C@H]1[C@@H](C)N(CC=2C=CC=CC=2)CC1 KRVOJOCLBAAKSJ-RDTXWAMCSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PQFKMERIBZZUKC-UHFFFAOYSA-N 1-(3-bromopropylsulfanyl)-2-chloro-4-fluorobenzene Chemical compound FC1=CC=C(SCCCBr)C(Cl)=C1 PQFKMERIBZZUKC-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- XAWPKHNOFIWWNZ-UHFFFAOYSA-N 1h-indol-6-ol Chemical compound OC1=CC=C2C=CNC2=C1 XAWPKHNOFIWWNZ-UHFFFAOYSA-N 0.000 description 1
- PEOVTCHEJYZMGX-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)sulfanyl-1-[4-(1h-indol-4-yl)piperazin-1-yl]ethanone Chemical compound ClC1=CC(F)=CC=C1SCC(=O)N1CCN(C=2C=3C=CNC=3C=CC=2)CC1 PEOVTCHEJYZMGX-UHFFFAOYSA-N 0.000 description 1
- FUSFWUFSEJXMRQ-UHFFFAOYSA-N 2-bromo-1,1-dimethoxyethane Chemical compound COC(CBr)OC FUSFWUFSEJXMRQ-UHFFFAOYSA-N 0.000 description 1
- DBTWOTKWIVISQR-UHFFFAOYSA-N 2-bromopropan-1-ol Chemical compound CC(Br)CO DBTWOTKWIVISQR-UHFFFAOYSA-N 0.000 description 1
- PWOBDMNCYMQTCE-UHFFFAOYSA-N 2-chlorobenzenethiol Chemical compound SC1=CC=CC=C1Cl PWOBDMNCYMQTCE-UHFFFAOYSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CSCKMYSAZZCGBM-UHFFFAOYSA-N 3-(2-chlorophenoxy)propan-1-ol Chemical compound OCCCOC1=CC=CC=C1Cl CSCKMYSAZZCGBM-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- ORJYEZRKBJPBBC-UHFFFAOYSA-N 4-[4-(4-phenylsulfanylbutyl)piperazin-1-yl]-1h-indole Chemical compound C1CN(C=2C=3C=CNC=3C=CC=2)CCN1CCCCSC1=CC=CC=C1 ORJYEZRKBJPBBC-UHFFFAOYSA-N 0.000 description 1
- GNXVSIIZXWQUSL-UHFFFAOYSA-N 4-[4-[2-(2-chlorophenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC=C1SCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 GNXVSIIZXWQUSL-UHFFFAOYSA-N 0.000 description 1
- GTEDGTAWEKFVAC-UHFFFAOYSA-N 4-[4-[2-(3,4-dichlorophenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound C1=C(Cl)C(Cl)=CC=C1SCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 GTEDGTAWEKFVAC-UHFFFAOYSA-N 0.000 description 1
- JYHGCUIXRPWVAR-UHFFFAOYSA-N 4-[4-[2-(4-fluorophenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound C1=CC(F)=CC=C1SCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 JYHGCUIXRPWVAR-UHFFFAOYSA-N 0.000 description 1
- KZEWQGCRIGPUPL-UHFFFAOYSA-N 4-[4-[3-(2,4,6-tribromophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC(Br)=CC(Br)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 KZEWQGCRIGPUPL-UHFFFAOYSA-N 0.000 description 1
- ZHVTYAWDPWFKPU-UHFFFAOYSA-N 4-[4-[3-(2-bromo-4,6-difluorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC(F)=CC(F)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 ZHVTYAWDPWFKPU-UHFFFAOYSA-N 0.000 description 1
- JWYLCHKTHHSISI-UHFFFAOYSA-N 4-[4-[3-(2-bromophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC=CC=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 JWYLCHKTHHSISI-UHFFFAOYSA-N 0.000 description 1
- RSWBUCLSNIHPEG-UHFFFAOYSA-N 4-[4-[3-(2-bromophenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC=CC=C1SCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 RSWBUCLSNIHPEG-UHFFFAOYSA-N 0.000 description 1
- MKBUROAPEBUIKK-UHFFFAOYSA-N 4-[4-[3-(2-chlorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 MKBUROAPEBUIKK-UHFFFAOYSA-N 0.000 description 1
- YSQABSAXRUXILH-UHFFFAOYSA-N 4-[4-[3-(2-chlorophenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC=C1SCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 YSQABSAXRUXILH-UHFFFAOYSA-N 0.000 description 1
- KWKZPKFLYOMNKF-UHFFFAOYSA-N 4-[4-[3-(3,4-dichlorophenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound C1=C(Cl)C(Cl)=CC=C1SCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 KWKZPKFLYOMNKF-UHFFFAOYSA-N 0.000 description 1
- LWYHEHOBDYUZNW-UHFFFAOYSA-N 4-[4-[3-(3-bromophenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC=CC(SCCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 LWYHEHOBDYUZNW-UHFFFAOYSA-N 0.000 description 1
- HUZGJIKTANDWGX-UHFFFAOYSA-N 4-[4-[3-(3-chlorophenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC(SCCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 HUZGJIKTANDWGX-UHFFFAOYSA-N 0.000 description 1
- NAIULWKBXNOWAL-UHFFFAOYSA-N 4-[4-[4-(2,4-dimethylphenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound CC1=CC(C)=CC=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 NAIULWKBXNOWAL-UHFFFAOYSA-N 0.000 description 1
- IMXGTWGIFMWAQJ-UHFFFAOYSA-N 4-[4-[4-(2,5-dichlorophenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=C(Cl)C(OCCCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 IMXGTWGIFMWAQJ-UHFFFAOYSA-N 0.000 description 1
- KNMMNHMEWIJBEX-UHFFFAOYSA-N 4-[4-[4-(2,6-dichlorophenyl)sulfanylbutyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC(Cl)=C1SCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 KNMMNHMEWIJBEX-UHFFFAOYSA-N 0.000 description 1
- YOTYVJKOHZCOJO-UHFFFAOYSA-N 4-[4-[4-(3,4-dimethoxyphenyl)sulfanylbutyl]piperazin-1-yl]-1h-indole Chemical compound C1=C(OC)C(OC)=CC=C1SCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 YOTYVJKOHZCOJO-UHFFFAOYSA-N 0.000 description 1
- IYUIXPNEWYBZFH-UHFFFAOYSA-N 4-[4-[4-(3-chlorophenyl)sulfanylbutyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC(SCCCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 IYUIXPNEWYBZFH-UHFFFAOYSA-N 0.000 description 1
- UYEMZRWXCBYHPZ-UHFFFAOYSA-N 4-[4-[4-(4-bromo-2,6-difluorophenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound FC1=CC(Br)=CC(F)=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 UYEMZRWXCBYHPZ-UHFFFAOYSA-N 0.000 description 1
- CLTGXJVCBSRZKL-UHFFFAOYSA-N BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=CC(=C1)F)Br.BrC1=CC(=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=C1)F)F Chemical compound BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=CC(=C1)F)Br.BrC1=CC(=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=C1)F)F CLTGXJVCBSRZKL-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PJACWUOCNXILTI-UHFFFAOYSA-N C(C(=O)O)(=O)O.BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound C(C(=O)O)(=O)O.BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 PJACWUOCNXILTI-UHFFFAOYSA-N 0.000 description 1
- VRDXWMKEJWCERN-UHFFFAOYSA-N C(C(=O)O)(=O)O.BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F Chemical compound C(C(=O)O)(=O)O.BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F VRDXWMKEJWCERN-UHFFFAOYSA-N 0.000 description 1
- QTRQUQIQCVPKOL-UHFFFAOYSA-N C(C(=O)O)(=O)O.ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound C(C(=O)O)(=O)O.ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 QTRQUQIQCVPKOL-UHFFFAOYSA-N 0.000 description 1
- PQAZPWIADRFDEL-UHFFFAOYSA-N C(C(=O)O)(=O)O.ClC1=C(C(=CC=C1)Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound C(C(=O)O)(=O)O.ClC1=C(C(=CC=C1)Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 PQAZPWIADRFDEL-UHFFFAOYSA-N 0.000 description 1
- OOUNHRBLKAFQHV-UHFFFAOYSA-N C(C)(C)C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.BrC=1C=C(C=CC1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound C(C)(C)C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.BrC=1C=C(C=CC1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 OOUNHRBLKAFQHV-UHFFFAOYSA-N 0.000 description 1
- KYACJQSTBUDANI-UHFFFAOYSA-N C1(=CC=CC=C1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.C(C)C1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.CC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)C Chemical compound C1(=CC=CC=C1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.C(C)C1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.CC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)C KYACJQSTBUDANI-UHFFFAOYSA-N 0.000 description 1
- QTFSZPLIQZUDMH-UHFFFAOYSA-N COC=1C=C(C=CC1OC)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=C(C=C1)Cl Chemical compound COC=1C=C(C=CC1OC)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=C(C=C1)Cl QTFSZPLIQZUDMH-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- QPYIHTQGLIGHFF-UHFFFAOYSA-N ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F Chemical compound ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F QPYIHTQGLIGHFF-UHFFFAOYSA-N 0.000 description 1
- VKUFSIFGTPSQLZ-UHFFFAOYSA-N ClC1=C(C=CC(=C1)F)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC1=CC=C(C=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC1=C(C=CC(=C1)F)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC1=CC=C(C=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 VKUFSIFGTPSQLZ-UHFFFAOYSA-N 0.000 description 1
- CEYVHNOMTJOHEI-UHFFFAOYSA-N ClC1=C(C=CC=C1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC1=C(C=CC=C1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 CEYVHNOMTJOHEI-UHFFFAOYSA-N 0.000 description 1
- SUOIKQLYFVXZGG-UHFFFAOYSA-N ClC1=C(C=CC=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC1=C(C=CC=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 SUOIKQLYFVXZGG-UHFFFAOYSA-N 0.000 description 1
- XVYPXKLVMOPHEJ-UHFFFAOYSA-N ClC=1C=C(C=CC1Cl)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC(C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F Chemical compound ClC=1C=C(C=CC1Cl)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC(C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F XVYPXKLVMOPHEJ-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003723 serotonin 1A agonist Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901889 | 1999-12-30 | ||
| PCT/DK2000/000742 WO2001049680A1 (en) | 1999-12-30 | 2000-12-29 | Novel indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK9452002A3 true SK9452002A3 (en) | 2002-11-06 |
Family
ID=8108836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK945-2002A SK9452002A3 (en) | 1999-12-30 | 2000-12-29 | Indole derivatives, pharmaceutical composition containing the same and their use |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030050307A1 (xx) |
| EP (1) | EP1246818A1 (xx) |
| JP (1) | JP2003519226A (xx) |
| KR (1) | KR20020063288A (xx) |
| CN (1) | CN1437598A (xx) |
| AR (1) | AR027134A1 (xx) |
| AU (1) | AU2352101A (xx) |
| BG (1) | BG106937A (xx) |
| BR (1) | BR0016955A (xx) |
| CA (1) | CA2395606A1 (xx) |
| CZ (1) | CZ20022489A3 (xx) |
| EA (1) | EA200200727A1 (xx) |
| HU (1) | HUP0203767A3 (xx) |
| IL (1) | IL150336A0 (xx) |
| IS (1) | IS6434A (xx) |
| MX (1) | MXPA02006498A (xx) |
| NO (1) | NO20023148L (xx) |
| NZ (1) | NZ519648A (xx) |
| PL (1) | PL355538A1 (xx) |
| SK (1) | SK9452002A3 (xx) |
| TR (1) | TR200201689T2 (xx) |
| WO (1) | WO2001049680A1 (xx) |
| ZA (1) | ZA200204969B (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002243394A1 (en) | 2000-11-16 | 2002-06-24 | Wyeth | Aryloxy piperidinyl derivatives for the treatment of depression |
| US6656950B2 (en) | 2001-04-25 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine |
| CA2451229C (en) * | 2001-06-29 | 2009-02-10 | H. Lundbeck A/S | Indole derivatives |
| ES2326078T3 (es) | 2002-08-22 | 2009-09-30 | Dainippon Sumitomo Pharma Co., Ltd. | Medicamento destinado al sindrome de la disfuncion de integracion. |
| CN1826338B (zh) | 2003-06-23 | 2011-07-13 | 大日本住友制药株式会社 | 老年性痴呆症治疗药 |
| US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
| AR055203A1 (es) * | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
| PL395469A1 (pl) * | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego |
| CN116554145A (zh) * | 2022-01-29 | 2023-08-08 | 江苏恩华药业股份有限公司 | 芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567884B1 (fr) * | 1984-07-19 | 1987-03-06 | Roussel Uclaf | Nouveaux derives de l'indole, leur preparation, leur application comme medicaments et les compositions les renfermant |
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| CN1155567C (zh) * | 1998-04-29 | 2004-06-30 | 惠氏公司 | 抑制精神的吲哚基衍生物 |
-
2000
- 2000-12-28 AR ARP000106989A patent/AR027134A1/es not_active Application Discontinuation
- 2000-12-29 WO PCT/DK2000/000742 patent/WO2001049680A1/en not_active Application Discontinuation
- 2000-12-29 CZ CZ20022489A patent/CZ20022489A3/cs unknown
- 2000-12-29 CN CN00819204A patent/CN1437598A/zh active Pending
- 2000-12-29 IL IL15033600A patent/IL150336A0/xx unknown
- 2000-12-29 MX MXPA02006498A patent/MXPA02006498A/es unknown
- 2000-12-29 PL PL00355538A patent/PL355538A1/xx not_active Application Discontinuation
- 2000-12-29 NZ NZ519648A patent/NZ519648A/en not_active Application Discontinuation
- 2000-12-29 KR KR1020027008609A patent/KR20020063288A/ko not_active Application Discontinuation
- 2000-12-29 TR TR2002/01689T patent/TR200201689T2/xx unknown
- 2000-12-29 CA CA002395606A patent/CA2395606A1/en not_active Abandoned
- 2000-12-29 BR BR0016955-2A patent/BR0016955A/pt not_active IP Right Cessation
- 2000-12-29 SK SK945-2002A patent/SK9452002A3/sk unknown
- 2000-12-29 AU AU23521/01A patent/AU2352101A/en not_active Abandoned
- 2000-12-29 EA EA200200727A patent/EA200200727A1/ru unknown
- 2000-12-29 JP JP2001550220A patent/JP2003519226A/ja not_active Withdrawn
- 2000-12-29 EP EP00987207A patent/EP1246818A1/en not_active Withdrawn
- 2000-12-29 HU HU0203767A patent/HUP0203767A3/hu unknown
-
2002
- 2002-06-19 IS IS6434A patent/IS6434A/is unknown
- 2002-06-20 ZA ZA200204969A patent/ZA200204969B/en unknown
- 2002-06-25 US US10/183,961 patent/US20030050307A1/en not_active Abandoned
- 2002-06-28 NO NO20023148A patent/NO20023148L/no not_active Application Discontinuation
- 2002-07-22 BG BG106937A patent/BG106937A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20022489A3 (cs) | 2002-10-16 |
| NO20023148D0 (no) | 2002-06-28 |
| ZA200204969B (en) | 2003-09-22 |
| MXPA02006498A (es) | 2002-11-29 |
| HUP0203767A2 (hu) | 2003-03-28 |
| WO2001049680A1 (en) | 2001-07-12 |
| AU2352101A (en) | 2001-07-16 |
| BR0016955A (pt) | 2003-04-29 |
| IL150336A0 (en) | 2002-12-01 |
| US20030050307A1 (en) | 2003-03-13 |
| CN1437598A (zh) | 2003-08-20 |
| PL355538A1 (en) | 2004-05-04 |
| BG106937A (en) | 2003-04-30 |
| JP2003519226A (ja) | 2003-06-17 |
| NO20023148L (no) | 2002-06-28 |
| AR027134A1 (es) | 2003-03-12 |
| KR20020063288A (ko) | 2002-08-01 |
| NZ519648A (en) | 2004-05-28 |
| EA200200727A1 (ru) | 2002-12-26 |
| IS6434A (is) | 2002-06-19 |
| TR200201689T2 (tr) | 2002-10-21 |
| EP1246818A1 (en) | 2002-10-09 |
| CA2395606A1 (en) | 2001-07-12 |
| HUP0203767A3 (en) | 2004-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6476035B1 (en) | Indole and 2,3-dihydroindole derivatives, their preparation and use | |
| SK10302001A3 (sk) | Piperidínové, tetrahydropyridínové a piperazínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie | |
| US6699864B2 (en) | Substituted phenyl-piperazine derivatives, their preparation and use | |
| NO20032636L (no) | 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser | |
| SK11062002A3 (sk) | Fenylpiperazínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie | |
| SK9452002A3 (en) | Indole derivatives, pharmaceutical composition containing the same and their use | |
| KR100792186B1 (ko) | 4-페닐-1-피페라지닐, -피페리디닐 및 -테트라히드로피리딜유도체 | |
| US20070173522A1 (en) | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | |
| US7342015B2 (en) | Indole derivatives | |
| SK1092003A3 (en) | Indole derivatives useful for the treatment of CNS disorders | |
| SK9432002A3 (en) | Novel heteroaryl derivatives, their preparation and use | |
| AU2002344950A1 (en) | Novel indole derivatives | |
| EP1468996B1 (en) | Indole derivatives for the treatment of CNS disorders | |
| PL190924B1 (pl) | Pochodne indolu i 2,3 - dihydroindolu, kompozycja farmaceutyczna oraz ich zastosowanie | |
| EA006315B1 (ru) | Производные индола, пригодные для лечения расстройств цнс | |
| SK512003A3 (en) | Indole derivatives useful for the treatment of CNS disorders |